1. Home
  2. INLF vs SERA Comparison

INLF vs SERA Comparison

Compare INLF & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INLF

INLIF LIMITED

HOLD

Current Price

$0.30

Market Cap

70.7M

Sector

Industrials

ML Signal

HOLD

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

HOLD

Current Price

$1.92

Market Cap

79.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLF
SERA
Founded
2016
2008
Country
China
United States
Employees
156
N/A
Industry
Industrial Machinery/Components
Precision Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.7M
79.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
INLF
SERA
Price
$0.30
$1.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.9M
96.7K
Earning Date
03-06-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.32
EPS
N/A
N/A
Revenue
N/A
$81,000.00
Revenue This Year
N/A
$875.93
Revenue Next Year
N/A
$248.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.19
52 Week Low
$0.29
$1.37
52 Week High
$1.78
$4.09

Technical Indicators

Market Signals
Indicator
INLF
SERA
Relative Strength Index (RSI) 41.10 40.13
Support Level N/A $1.72
Resistance Level $0.58 $2.00
Average True Range (ATR) 0.06 0.22
MACD -0.00 0.03
Stochastic Oscillator 1.76 30.86

Price Performance

Historical Comparison
INLF
SERA

About INLF INLIF LIMITED

INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. Its portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: